NCT06263361 Improving Safety and Accuracy of Stereotactic Brain Biopsies in Primary Central Nervous System Lymphoma.
| NCT ID | NCT06263361 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS San Raffaele |
| Condition | Cerebral Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 15 participants |
| Start Date | 2021-10-01 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 15 participants in total. It began in 2021-10-01 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Primary central nervous system lymphoma (PCNSL) is an aggressive extranodal non- Hodgkin lymphoma exclusively localized into the nervous system. The aim of this study is to evaluate the MRI imaging characteristics of the peritumoral area (PTA) and to correlate this information to pathological findings.
Eligibility Criteria
Inclusion Criteria: * Adult patients, undergoing stereotactic biopsy for newly diagnosed PSNCLs Exclusion Criteria: * Severe hepatic dysfunction * Severe renal dysfunction * Severe heart failure * myocardial infarction and stroke within 90 days * Hyperreactivity against contrast agents * Pregnancy
Contact & Investigator
Pietro Mortini, MD, Prof.
STUDY DIRECTOR
IRCCS San Raffaele Scientific Institute
Frequently Asked Questions
Who can join the NCT06263361 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cerebral Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06263361 currently recruiting?
Yes, NCT06263361 is actively recruiting participants. Contact the research team at sincinelli.laura@hsr.it for enrollment information.
Where is the NCT06263361 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT06263361 clinical trial?
NCT06263361 is sponsored by IRCCS San Raffaele. The principal investigator is Pietro Mortini, MD, Prof. at IRCCS San Raffaele Scientific Institute. The trial plans to enroll 15 participants.